バゾプレッシン誘導体DDAVPによる尿崩症の治験成績-37施設による共同研究-

• 田苗 綾子

  国立小児病院 内分泌代謝科

• 清水 倉二

  東京大学医学部第一内科

• 吉田 尚

  自治医科大学内分泌代謝科

書誌事項

タイトル別名

• The Treatment of Patients with Diabetes Insipidus by a Synthetic Analogue of Vasopressin, DDAVP
• バゾプレッシン ユウドウタイ DDAVP ニヨル ニョウホウショウ ノ チケン

抄録

The effects of a synthetic analogue of vasopressin, DDAVP (1-deamino-8-D-arginine vasopressin) were investigated in 98 patients with cranial diabetes insipidus. In all patients, intranasal administration of DDAVP one to three times daily, usually twice daily, was found to be satisfactory in the control of diabetes insipidus. Thus, by DDAVP administration, daily urinary volume changed from 3520±2150 ml to 1620 ±830 ml (mean± SD), and urinary osmolarity changed from 126±75 mOsm/kgH₂O to 446-194 mOsm/kgH₂O (mean ±SD). A daily dose of DDAVP ranged from 2.0 to 20 μg in children (average dose 12.8 μg), while 10 to 20μEg of DDAVP was usually required in adult patients (average dose 14.2 pg). No serious side effects have been observed. It is concluded that DDAVP is safe and effective in the treatment of cranial diabetes insipidus.

収録刊行物

• Folia Endocrinologica Japonica

  Folia Endocrinologica Japonica 54 (5), 676-691, 1978

  The Japan Endocrine Society

詳細情報

• CRID: 1390001206438728448
• NII論文ID: 130001938370
• NII書誌ID: AN00195891
• DOI: 10.1507/endocrine1927.54.5_676
• COI: 1:STN:280:DyaE1M%2FgtlOqsA%3D%3D
• NDL書誌ID: 1944535
• ISSN: 00290661
• PubMed: 689212
• Web Site: https://ndlsearch.ndl.go.jp/books/R000000004-I1944535
• Web Site: https://www.jstage.jst.go.jp/article/endocrine1927/54/5/54_676/_pdf
• Web Site: https://search.jamas.or.jp/link/ui/1979049346
• 本文言語コード: ja
• データソース種別:
  • JaLC
  • NDL
  • Crossref
  • PubMed
  • CiNii Articles
• 抄録ライセンスフラグ: 使用不可